Audit: QRS - Obicetrapib for Health & Longevity

Audit conducted on 07/08/2026 16:29 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values (10 mg once daily, plus ezetimibe 10 mg, 1.6-fold food effect, 48.6% placebo-adjusted reduction), time-to-effect values, benefit/risk tier items, gate items, monitoring targets and cadence trace to ER lines 411–425, 466, 161–239, 265–337, 355–385 and 490–516.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Any effect on events, if real”, “Biomarker movement is not clinical benefit”, “no cognitive benefit has been demonstrated”, “Best time of day is not established” all carry the ER’s hedging forward.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	St John’s wort remains an absolute contraindication (ER line 375) and stays in the Contraindications gate; caution-level interactions stay in Key Interactions.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from ER Key Interactions & Contraindications; Benefits from Expected Benefits; Risks from Potential Risks & Side Effects; no Benefit- or Risk-Modifying Factor is surfaced.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, author names, NCT identifiers or brand names (Ubeslo, Evlarco) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, sceptical register of the ER Conclusion is preserved, including the sponsor-independence caveat.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified protocol and monitoring targets sit alongside plain-language framing; the sheet enables an informed decision rather than closing one off.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as observed evidence and reference ranges, not as instructions to an individual.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a reader; monitoring and cadence entries are descriptive and mirror the ER’s own wording.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise”, “should” or equivalent appears in the document’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms appear only where the ER itself uses them (monitoring markers, drug classes); the At-A-Glance is entirely plain.
2.8	Information is presented in a concise and very compact manner	🟢	Benefits, Risks and gate items are terse fragments; no explanatory prose is carried over.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan; no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing assumes someone already on maximally tolerated therapy and short of an ApoB target.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	A 12-marker panel, repeat testing at 12 weeks and 6 months, and biennial dilated retinal examination assume high willingness to act.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Optimal functional ranges (ApoB < 60, ALT < 25 U/L, potassium 4.0–4.5 mmol/L) are tighter than conventional laboratory flags.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The cumulative particle-years framing, the life-expectancy gate and the Lp(a) emphasis are longevity-audience specific.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” is used in the title; “anti-aging” appears nowhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Oral medication”, “single daily tablet”, “adverse events”, “acute coronary syndrome” are used; no consumer-grade substitutes.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and table column headers match the template byte-for-byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variable names are present; the repeatable marker_#_* and qualitative_item_# rows are expanded to 12 and 6 concrete instances respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A structural diff against the template shows no change outside variable regions and the metadata block; CSS, comments and DOM structure are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section feeding the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (“Standard protocol”, “The fixed-dose combination approach”, “Administration with or without food”) and all six Qualitative Assessment labels are the ER’s bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring marker names are the ER table’s biomarker names verbatim; Time-to-Effect labels are lifted from the ER’s own phrasing at line 466.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file; the ER’s ⚠️ Conflicted markers were stripped from the transferred headings.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to key fragments within the template’s single-sheet structure; no content is extended beyond the template’s own layout.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 precedes the opener.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed elsewhere on the page.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly so because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: obicetrapib_2026-0807-1203_Opus_ER.md (line 4).
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 (line 5), matching QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0807-1606 (line 6).
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus (line 7).
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5 (line 8).
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: obicetrapib_2026-0807-1203_Opus_QRS.html (line 9), matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Obicetrapib for Health & Longevity - Quick Reference Sheet” (line 22).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Obicetrapib for Health & Longevity” (line 417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0807-1606 → “08/07/2026” (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header contains only the title and the template’s own subline; the ER’s alternate names (TA-8995, AMG-899, DEZ-001, Ubeslo) are not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three Conclusion paragraphs: mechanism, lipid effect, tolerability, the unresolved outcomes question and the sponsor concentration.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to ER lines 550, 552 and 554 respectively.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“blood protein”, “plaque-forming particles”, “inherited particle type”, “inactive treatment” replace CETP, ApoB-containing particles, Lp(a) and placebo.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, sample size or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No percentages, hazard ratios or confidence intervals.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items trace to ER lines 375 and 385.
8.2	[stop_items] represent the Contraindications from the ER	🟢	St John’s wort (absolute contraindication) plus all six populations from “Populations who should avoid this intervention” are present, with none omitted.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements inside the stop_items span (lines 582–588).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER rationales (“no data, four-month washout”, “excluded from the phase 3 trials”, “not studied, and moderate impairment already alters exposure”) are all stripped; no dash-trailing clause remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(Child-Pugh Class C)”, “within 90 days”, “above three times the upper limit of normal” and “eGFR below 30 mL/min/1.73 m²” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER contraindication bullets use no ranking notation inside parentheses.
8.7	If no [stop_items] are present the section is left empty	N/A	Seven stop items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All 13 items trace to ER lines 357–383.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All 13 non-contraindication interaction bullets are carried over; St John’s wort is correctly excluded and appears only in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Thirteen <li> elements inside the caution_items span (lines 596–614).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “Over-the-counter medications —”, “Supplement interactions —” and “Other interventions —” prefixes and all mitigating-action prose are stripped; only the agent names remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every named example list is retained, including the CYP3A4 inhibitor and inducer lists, “(fenofibrate, gemfibrozil)”, “(ethinyl estradiol/drospirenone)”, “(atorvastatin 40–80 mg, rosuvastatin 20–40 mg)”, “(evolocumab, alirocumab)” and “(psyllium, beta-glucan)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets use no ranking notation inside parentheses.
9.7	If no [caution_items] are present the section is left empty	N/A	Thirteen caution items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol lines 411, 413, 415 and 419–425.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose and duration, the fixed-dose combination versus sequential route, and administration relative to food are the three decisions a reader actually has to make.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	All three action sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine fields carry substantive ER-derived content; no placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Lipid changes, cardiovascular events and brain biomarkers are exactly the three horizons given in the ER’s “Time to effect” bullet (line 466).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Lipid changes map to the High benefit tier and lead; cardiovascular events and Alzheimer’s biomarkers are both Medium tier and follow.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	All three time sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine fields are populated from ER lines 466 and 203.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides explicit time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All 13 items are the ER’s benefit sub-headings from lines 163–239.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present and populated at the matching ER tier.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Semicolon-separated heading fragments only; the ER’s Magnitude figures and evidence-basis prose are entirely absent.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content is carried over; the only parentheses are part of the term “lipoprotein(a)”.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All 12 items are the ER’s risk sub-headings from lines 267–337.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present and populated at the matching ER tier.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Heading fragments only; torcetrapib hazard ratios, adverse-event percentages and washout figures are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any of the four risk spans.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Marker names, targets and “why” text are taken from the ER Monitoring Protocol & Defining Success table at lines 496–507.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 12 ER table rows appear: ApoB, LDL-C, Lp(a), non-HDL-C, HDL-C, hs-CRP, ALT/AST, creatine kinase, creatinine with eGFR, potassium, glycated hemoglobin and seated blood pressure.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline, 12 weeks, 6 months, then 6–12 monthly, plus the blood-pressure and biennial retinal schedules, matching ER lines 490–492.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items derive from the qualitative markers at ER lines 511–516.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six are present: absence of new symptoms, muscle comfort, visual clarity, cognitive clarity, sleep and energy, adherence.

Issues 07/08/2026 16:29

Pass rate 100.00%. No issues found.

Issues 07/08/2026 16:21

1. 9.2 — NSAID interaction bullet omitted: The ER’s Key Interactions & Contraindications bullet for non-steroidal anti-inflammatory drugs (ER line 373) is not represented in [caution_items] (QRS lines 596–613), although it is neither a contraindication nor otherwise covered.

Fixes 07/08/2026 16:21

1. 9.2 — NSAID interaction bullet added: Added <li>Non-steroidal anti-inflammatory drugs</li> to [caution_items], after “Cimetidine and high-dose omeprazole”, so the Key Interactions gate now carries every non-contraindication bullet from the ER Key Interactions & Contraindications section.

Issues 07/08/2026 16:09

1. 1.3 — NSAIDs presented as an interaction: The Key Interactions gate lists “Non-steroidal anti-inflammatory drugs” (QRS line 606), but ER line 373 states “No known interaction with obicetrapib itself”, so the QRS turns a stated non-interaction into a decision-gate item.
2. 2.7 — Unexpanded LDL-C acronym: QRS line 471 uses “LDL-C” in action_2_sub while the rest of the document spells out “LDL cholesterol” (lines 547, 683), leaving an unexplained acronym in the Protocol panel.

Fixes 07/08/2026 16:09

1. 1.3 — NSAIDs removed from Key Interactions: Deleted the “Non-steroidal anti-inflammatory drugs” item from caution_items, since ER line 373 states there is no known interaction with obicetrapib itself.
2. 2.7 — Unexpanded LDL-C acronym: Changed “48.6 percent placebo-adjusted LDL-C reduction” to “48.6 percent placebo-adjusted LDL cholesterol reduction” in action_2_sub, matching the full form used elsewhere in the QRS.